252 related articles for article (PubMed ID: 20648926)
21. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.
Grimmelt AC; Cohen CD; Fehr T; Serra AL; Wuethrich RP
Clin Nephrol; 2009 Feb; 71(2):125-9. PubMed ID: 19203504
[TBL] [Abstract][Full Text] [Related]
24. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
Calvet X; Ruíz MÀ; Dosal A; Moreno L; López M; Figuerola A; Suarez D; Miquel M; Villoria A; Gené E
PLoS One; 2012; 7(9):e45604. PubMed ID: 23029129
[TBL] [Abstract][Full Text] [Related]
25. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
[TBL] [Abstract][Full Text] [Related]
26. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
27. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Evstatiev R; Alexeeva O; Bokemeyer B; Chopey I; Felder M; Gudehus M; Iqbal T; Khalif I; Marteau P; Stein J; Gasche C;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
[TBL] [Abstract][Full Text] [Related]
28. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
[TBL] [Abstract][Full Text] [Related]
29. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
Seid MH; Derman RJ; Baker JB; Banach W; Goldberg C; Rogers R
Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998
[TBL] [Abstract][Full Text] [Related]
30. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
31. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
Tagboto S; Cropper L; Turner J; Pugh-Clarke K
J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
[TBL] [Abstract][Full Text] [Related]
33. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
Calvet X; Gené E; ÀngelRuíz M; Figuerola A; Villoria A; Cucala M; Mearin F; Delgado S; Calleja JL
Technol Health Care; 2016; 24(1):111-20. PubMed ID: 26409561
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
35. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
36. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
37. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia.
Calleja JL; Delgado S; del Val A; Hervás A; Larraona JL; Terán Á; Cucala M; Mearin F;
Int J Colorectal Dis; 2016 Mar; 31(3):543-51. PubMed ID: 26694926
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
Hofmarcher T; Borg S
J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
[TBL] [Abstract][Full Text] [Related]
39. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
40. An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization.
Tabasi O; Razlighi MR; Darbandi MA
Pharm Nanotechnol; 2021; 9(2):157-163. PubMed ID: 33459254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
